non-coding RNA
Broad Institute and Northwestern University researchers are encouraging others to examine noncoding genes, when investigating undiagnosed rare diseases.
One independent researcher called the study "a valuable guide for experimental validation of circRNAs" in cancer and neurodegenerative disease research.
Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial
The collaborators are using Exai's oncRNA-based liquid biopsy tech in predicting clinical outcomes and treatment response in the I-SPY 2 trial.
The company is assessing a variety of applications, including cancer early detection, using algorithms to analyze orphan noncoding RNA in blood.
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.